Core Insights - Guofa Co., Ltd. (600538) has announced the appointment of a special auditing firm for a simplified procedure to issue A-shares to specific investors, with a total financing amount not exceeding 300 million yuan [1] - The company is focused on the health sector, covering pharmaceutical manufacturing, distribution, and IVD (in vitro diagnostics) [1] - A new diversified executive team has been established, including Chairman Jiang Ye and President Zhang Xiaowei, to drive the company's new development strategy [1] Company Developments - The IVD industry is transitioning from "single testing" to "precision and full-cycle management," with companies having core technological breakthroughs and global integration advantages becoming more competitive [1] - Guofa's subsidiary, Gao Sheng Bio, has developed an ultra-micro DNA automatic extraction workstation, enhancing automation in sample preparation and achieving success in forensic DNA second-generation sequencing library construction [1] - The company plans to focus on brand marketing for its eye drop product "Haibao" this year, which is recognized as a key technological innovation project and included in the national medical insurance and essential drug list [2] Strategic Initiatives - In late July, Chairman Jiang Ye led a visit to DaoKe Technology, a leading cloud-native operating system company, signaling the company's exploration into the AI field [2]

Meeting Overview - The 10th meeting of the 11th Supervisory Board of Beihai Guofa Chuanshan Biological Co., Ltd. was held on July 31, 2025, with all three supervisors participating in the voting [2][5] - The meeting was legally convened and chaired by Mr. Lü Qiujun [2] Audit Institution Appointment - The Supervisory Board approved the proposal to appoint Shanghai Shuhui Accounting Firm (Special General Partnership) as the special audit institution for the company's 2025 A-share issuance to specific targets [3][8] - The appointment does not require submission to the shareholders' meeting for approval [4] Audit Institution Details - Shanghai Shuhui Accounting Firm was established in January 1981 and has undergone several transformations, with its current form established in December 2013 [8] - The firm has provided audit services to 72 listed companies in 2024, with a total audit revenue of 0.81 billion yuan [9] - The firm has a total revenue of 0.683 billion yuan in 2024, with 0.204 billion yuan from securities business [9][10] Voting Results - The proposal received unanimous support from the Supervisory Board, with 3 votes in favor and no opposition or abstentions, representing 100% of the valid voting rights [5] Board Meeting Overview - The 17th meeting of the 11th Board of Directors was also held on July 31, 2025, with all 9 directors participating [21] - The Board approved the proposal to appoint the same audit institution for the 2025 A-share issuance, with a unanimous vote of 9 in favor [32][33] Financing Guarantee - The company agreed to provide a guarantee for its wholly-owned subsidiary, Beihai Guofa Pharmaceutical Co., Ltd., for a loan of 20 million yuan from China Postal Savings Bank [29][34] - The loan term is set for 3 years, and the company will not charge any guarantee fees [34][41] - The total amount of external guarantees before this loan was 0 yuan, and the new guarantee represents 2.58% of the company's audited net assets [44]

Core Viewpoint - The company has approved the appointment of a special auditing firm for the issuance of A-shares to specific targets in 2025, ensuring compliance with relevant regulations and standards [1] Group 1: Meeting Details - The 2025 third meeting of the Board of Directors' Audit Committee was held via communication voting, with all 3 members present [1] - The committee unanimously approved the proposal to hire a special auditing firm for the 2025 A-share issuance [1] Group 2: Audit Firm Evaluation - The Audit Committee conducted a thorough evaluation of the appointed auditing firm, assessing its independence, professional competence, investor protection capability, and integrity [1] - The auditing firm possesses qualifications for auditing securities, futures, and related businesses, along with extensive experience in auditing listed companies [1] - The committee concluded that the auditing firm meets the requirements for the 2025 A-share issuance audit work [1]

证券代码：600538 证券简称：国发股份 公告编号：临 2025-035 北海国发川山生物股份有限公司 表决结果：同意 8 票，反对 0 票，弃权 1 票，同意票占董事会有效表决权 的 88.89%。 经公司董事长提名，董事会审议，同意补选独立董事董秋红女士为公司第 十一届董事会战略委员会委员，任期至本届董事会任期届满之日止。 本次补选后，公司董事会战略委员会委员为姜烨先生（主任委员）、张小玮 先生、彭韬先生、董秋红女士（独立董事）、尹志波先生，符合《公司董事会战 略委员会工作细则》中战略委员会成员组成的要求。 董事彭韬先生对本议案投了弃权票，理由为"没有独董经验"。 表决结果：同意 8 票，反对 0 票，弃权 1 票，同意票占董事会有效表决权 的 88.89%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）第十一届董事会第十 七次会议于 2025 年 7 月 31 日在公司二楼会议室以现场及通讯表决方式召开， 会议通知及会议资料于 2025 年 7 月 25 日以微信及电 ...

Group 1 - The company announced the approval of multiple proposals during the 17th meeting of the 11th Board of Directors, including the election of new members for the specialized committees [2]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，国发股份发布公告称，公司第十一届监事会第十次会议审议通过了《关于 2025年度以简易程序向特定对象发行A股股票聘请专项审计机构的议案》。 ...

Group 1 - The company Guofa Co., Ltd. (SH 600538) announced the convening of its 11th Board of Directors' 17th meeting on July 31, 2025, to discuss the election of new committee members [2] - For the fiscal year 2024, the revenue composition of Guofa Co., Ltd. is as follows: pharmaceutical distribution accounts for 53.64%, judicial appraisal for 34.87%, pharmaceutical manufacturing for 10.41%, other businesses for 0.64%, and other categories for 0.44% [2]

证券代码：600538 证券简称：国发股份 公告编号：临 2025-037 北海国发川山生物股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 北海国发医药有限责任公司 | 2,000.00 万元 | | --- | --- | --- | --- | | 担保对 象 | 实际为其提供的担保余额 | | 0 万元 | | | 是否在前期预计额度内 | □是 否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 2,000 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 2.58 | | 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 100 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2025-038 北海国发川山生物股份有限公司 关于聘请公司专项审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示：拟聘任的会计师事务所名称：上会会计师事务所（特殊普通 合伙）（以下简称"上会会计师事务所"或"上会所"）。 北海国发川山生物股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日 召开的第十一届董事会第十七次会议、第十一届监事会第十次会议审议通过了 《关于 2025 年度以简易程序向特定对象发行 A 股股票聘请专项审计机构的议案》， 同意聘请上会会计师事务所为公司 2025 年度以简易程序向特定对象发行 A 股股 票的专项审计机构。现将相关情况公告如下： 一、聘任专项审计机构的基本情况 （一）审计机构信息 1、基本信息 上会所原名上海会计师事务所，成立于 1981 年 1 月，系财政部在上海试点 成立的全国第一家会计师事务所。1998 年 12 月按财政部、中国证券监督管理委 员会的要求，改制为上海上会会计师事务所有限 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2025-036 北海国发川山生物股份有限公司 第十一届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北海国发川山生物股份有限公司（以下简称"公司"）第十一届监事会第十次 会议于 2025 年 7 月 31 日在公司二楼会议室以现场及通讯方式召开，会议通知及 会议资料于 2025 年 7 月 25 日以电子邮件方式发出。本次会议应参与表决监事 3 人，实际参与表决监事 3 人。会议由监事会主席吕秋军先生主持，会议的召集、 召开和表决符合《公司法》及《公司章程》的有关规定，会议召开合法有效。 二、监事会会议审议情况 本议案无需提交股东大会审议。 具体内容详见公司 2025 年 8 月 1 日在《中国证券报》《证券时报》《证券日报》 《上海证券报》和上海证券交易所网站（https://www.sse.com.cn）披露的《关 于聘请公司专项审计机构的公告》（临 2025-038）。 1 表决结果：同意【3】票，反对【0】票 ...